Background
Phase III, open-label RCT. 1486 patients with HER2+ early breast cancer who had residual invasive disease in the breast or axilla after neoadjuvant taxane- and trastuzumab-based therapy (pathologic non-pCR). T-DM1 (trastuzumab emtansine) delivers the cytotoxic DM1 (maytansinoid) directly to HER2+ cells. Based on hypothesis that residual disease after NACT represents a high-risk, partially treatment-resistant population.
Interventions and follow up
Arm A: T-DM1 (trastuzumab emtansine) 3.6mg/kg IV q21d × 14 cycle
Arm B: Trastuzumab 6mg/kg q21d × 14 cycle
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 41.4 month
Arm B: Trastuzumab 6mg/kg q21d × 14 cycle
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 41.4 month
Results
IDFS: HR 0.50, 95% CI 0.39–0.64, P<.001
3-yr IDFS: 88.3% vs 77.0% (absolute benefit ~11.3%)
DRFI: HR 0.60, 95% CI 0.45–0.79
3-yr IDFS: 88.3% vs 77.0% (absolute benefit ~11.3%)
DRFI: HR 0.60, 95% CI 0.45–0.79
Adverse events
Hematologic: grade ≥3 platelet count decreased 6.3% vs 0.6%
Neurologic: peripheral neuropathy any grade 22.3% (grade ≥3 2.4% vs 0.2%)
Hepatic: grade ≥3 hepatotoxicity 2.7%
Cardiac: symptomatic LVEF decline 0.3%
Other: discontinuation 18.0% vs 2.1%
Neurologic: peripheral neuropathy any grade 22.3% (grade ≥3 2.4% vs 0.2%)
Hepatic: grade ≥3 hepatotoxicity 2.7%
Cardiac: symptomatic LVEF decline 0.3%
Other: discontinuation 18.0% vs 2.1%
Conclusions
T-DM1 significantly improved IDFS vs trastuzumab in HER2+ early BC with residual disease after NACT, reducing the relative risk of recurrence or death by 50%. The 11.3% absolute benefit at 3 years represents one of the largest adjuvant benefits reported in breast oncology.
Key Limitations
Key Limitations: Open-label design — assessor bias possible, though IDFS events are objective. T-DM1 discontinuation was high (18%) due to cumulative peripheral neuropathy and thrombocytopenia. 14 cycles (14 × 3 weeks = ~10 months) is a relatively long treatment course with cumulative toxicity. Not all patients can complete the full course. HER2-low residual disease (IHC 2+/ISH– patients, if any) and subsequent T-DXd data (DESTINY-Breast05) are superseding T-DM1 in some contexts.
Clinical Context
KATHERINE established T-DM1 as the standard of care for HER2+ early BC with residual disease post-NACT (FDA approved 2019; ESMO-MCBS score: 5). This trial transformed the adjuvant HER2+ paradigm to a "response-adapted" approach: pCR → standard trastuzumab completion; non-pCR → T-DM1 escalation. DESTINY-Breast05 (2024) subsequently showed T-DXd is superior to T-DM1 in this residual-disease setting, now emerging as the new standard.
References
References: von Minckwitz G et al, NEJM 2019